| Literature DB >> 23487362 |
Krzysztof Ficek1, Tomasz Kamiński, Ewa Wach, Jerzy Cholewiński, Paweł Cięszczyk.
Abstract
Any new method of treatment is associated with high expectations for its success, particularly if the therapy is based not only on the premise of achieving a symptomatic effect, but also improving functional quality and repairing structurally damaged tissues. Platelet Rich Plasma (PRP) application was shown to be a successful catalyst in the healing process for a wide variety of conditions in animal and human models. However, its use has been controversial due to many types of the PRP definition, optimal concentration, and modalities of implementation. In the qualification of patients for PRP treatment, not only should medical indications be considered, but also the role of participation in therapy with a physiotherapist supervising physical parameters and techniques used during recovery time. Further study is required in order to define optimal handling procedures of PRP injection. Long-term follow up will reveal if the promise of this substance can be realized and implemented to maximize its potential as a therapeutic remedy.Entities:
Keywords: Platelet-rich plasma; musculoskeletal injuries; tendinopathy
Year: 2011 PMID: 23487362 PMCID: PMC3588629 DOI: 10.2478/v10078-011-0076-z
Source DB: PubMed Journal: J Hum Kinet ISSN: 1640-5544 Impact factor: 2.193
Platelet growth factors
| Factor | Parameter |
|---|---|
| EGF | Stimulates the proliferation of epithelial cells, fibroblasts, is a chemoattractant for these cells, stimulates epithelialization, and affects the synthesis and metabolism of the extracellular matrix. |
| PDGF | Both isoform A and B are powerful |
| TGF-α | Similar to EGF, binds to the same receptor, stimulates the growth of mesenchymal cells, endothelial and epithelial cells, but also factors in its development. Affects bone formation and regeneration. |
| TGF-β1 | Stimulates chemotaxis of fibroblasts, collagen synthesis, reduces scarring of the skin, inhibits the growth of epithelial cells, fibroblasts, nerve cells, keratinocytes, and hematopoiesis. Acts in opposition to EGF, PDGF, aFGF, bFGF. It inhibits DNA synthesis in human fibroblasts and control of apoptosis. |
| KGF | Strongest for keratinocyte growth factor, is involved in wound healing through proliferation, differentiation, angiogenesis and cell migration, additionally is a myogen/myocyte for many epithelial cells with the exception of endothelial cells and fibroblasts. Increases collagen production by creating a support substance for the skin. |
| a-FGF or FGF-1 | Participates in the processes as those above, is a |
| b-FGF or FGF-2 | Stimulates KGF production, angiogenesis, wound contraction, collagen and matrix synthesis. |
| VEGF/VEP | Stimulates endothelium in large blood vessels, a protein with strong features of angiogenesis, initiates the regeneration of blood supply, causes degradation of metaloprotein synthesis in interstitial collagen types 1, 2 and 3 |
| CTGF | Initiates proliferation, migration, and curling up of vascular endothelial cells, proliferation and differentiation of osteoblasts, mineralization of the matrix. |
| GM-CSF lub CSF α | Proliferates and differentiates osteoblasts, the synergism of erythropoietin in the proliferation of bone marrow stem cells, is a strong chemoatractant for neutrophils, increases expression of selectin, integrins and adhesion molecules of the immunoglobulin superfamily. |
| TNF-α | Growth factor for fibroblasts, it accelerates angiogenesis, inhibits keratinocyte proliferation and growth, participates in the post burn reactions. |
| IGF | Growth factor for normal fibroblasts, enhances synthesis of collagenase and PGE 2 in fibroblasts, regulates the metabolism of articular cartilage through an increased synthesis of collagen and matrix osteon. |
| IL-1β | Inhibits the growth of endothelial cells and hepatocytes, activates osteoclasts (albeit at low concentrations, promotes new bone growth) enhances infection and collagenase activity. Enhances the infection processes in the skin and also strongly stimulates fibroblasts. |
| IL-6 | Mature fibroblasts and macrophages produce IL-6, which stimulates the growth of fibroblasts and collagen production, pro infectious cytokine. In the form associated with blocking protein, inhibits the growth of fibroblasts and collagen production, IL-8 supports angiogenesis and is mitogenic for epithelial cells. |
| IL-8 |